Gilead Sciences Retained Earnings increased by 2.9% to $14.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.3%, from $10.93B to $14.13B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows relatively stable performance with a -0.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
retained_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.39B | $16.90B | $16.32B | $14.99B | $15.12B | $15.76B | $15.69B | $15.22B | $15.14B | $16.00B | $16.30B | $10.66B | $11.17B | $11.07B | $11.50B | $10.93B | $11.33B | $12.83B | $13.73B | $14.13B |
| QoQ Change | — | +9.8% | -3.4% | -8.2% | +0.9% | +4.2% | -0.4% | -3.0% | -0.6% | +5.7% | +1.9% | -34.6% | +4.8% | -0.8% | +3.8% | -4.9% | +3.6% | +13.2% | +7.1% | +2.9% |
| YoY Change | — | — | — | — | -1.8% | -6.8% | -3.9% | +1.6% | +0.1% | +1.6% | +3.9% | -30.0% | -26.2% | -30.8% | -29.5% | +2.6% | +1.4% | +15.8% | +19.4% | +29.3% |